ECO Animal Health Group (LON:EAH) Share Price Crosses Above 50 Day Moving Average – What’s Next?

ECO Animal Health Group plc (LON:EAH) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 68.99 ($0.93) and traded as high as GBX 73.97 ($1.00). ECO Animal Health Group shares last traded at GBX 73.27 ($0.99), with a volume of 30,828 shares.

Analyst Ratings Changes

Separately, Shore Capital reissued a “buy” rating and issued a GBX 150 price target on shares of ECO Animal Health Group in a report on Monday, July 14th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of GBX 150.

ECO Animal Health Group Stock Down 0.3%

The company has a debt-to-equity ratio of 4.81, a current ratio of 2.96 and a quick ratio of 2.14. The company has a fifty day moving average price of GBX 68.99 and a 200 day moving average price of GBX 62.57. The company has a market cap of £49.64 million, a PE ratio of 47.36 and a beta of -0.05.

ECO Animal Health Group (LON:EAH) last announced its earnings results on Monday, July 14th. The company reported GBX 2.49 earnings per share for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Insider Transactions at ECO Animal Health Group

In related news, insider David Hallas bought 29,897 shares of the business’s stock in a transaction that occurred on Tuesday, July 15th. The stock was bought at an average cost of GBX 67 per share, for a total transaction of £20,030.99. Company insiders own 21.65% of the company’s stock.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.